阿斯利康因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股

路透中文

07/09

BUZZ-<a href="https://laohu8.com/S/AZN">阿斯利康</a>因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股

7月9日 - ** 阿斯利康（AZN.L）股價一度暴跌9.6%至12,874便士；有望創下自2017年以來最慘淡的一天

** AZN成為富時100指數 .FTSE 中跌幅最大的個股，該指數下跌0.4%

** 該公司表示，其與Ionis（IONS.O）合作研發的神經疾病藥物Wainua，在晚期臨床試驗中 (link) 未能達到降低心血管死亡率及心血管疾病複發率的主要目標

** 今年以來，AZN股價下跌6%

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2650941777"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650941777\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650941777?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-09 15:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650941777","market":"us","top_or_hot":-1,"title":"阿斯利康因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股</title></head><body><p>\n<span>7月9日</span><span> - </span>** 阿斯利康（<span>AZN.L</span>）股價一度暴跌9.6%至12,874便士；有望創下自2017年以來最慘淡的一天</p><p>** AZN成為富時100指數 <span>.FTSE</span> 中跌幅最大的個股，該指數下跌0.4%</p><p>** 該公司表示，其與Ionis（<span>IONS.O</span>）合作研發的神經疾病藥物Wainua，在晚期臨床試驗中 (<span>link</span>) 未能達到降低心血管死亡率及心血管疾病複發率的主要目標</p><p>** 今年以來，AZN股價下跌6%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-07-09 15:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股</title></head><body><p>\n<span>7月9日</span><span> - </span>** 阿斯利康（<span>AZN.L</span>）股價一度暴跌9.6%至12,874便士；有望創下自2017年以來最慘淡的一天</p><p>** AZN成為富時100指數 <span>.FTSE</span> 中跌幅最大的個股，該指數下跌0.4%</p><p>** 該公司表示，其與Ionis（<span>IONS.O</span>）合作研發的神經疾病藥物Wainua，在晚期臨床試驗中 (<span>link</span>) 未能達到降低心血管死亡率及心血管疾病複發率的主要目標</p><p>** 今年以來，AZN股價下跌6%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0976567544.SGD","symbol_name":"FTIF - Templeton Global Income A Mdis SGD-H1","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nL4S43B0KZ:1","article_id":"2650941777","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650941777","pubTimestamp":1783581986,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-阿斯利康因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股7月9日-** 阿斯利康（AZN.L）股價一度暴跌9.6%至12,874便士；有望創下自2017年以來最慘淡的一天** AZN成為富時100指數.FTSE中跌幅最大的個股，該指數下跌0.4%** 該公司表示，其與Ionis（IONS.O）合作研發的神經疾病藥物Wainua，在晚期臨床試驗中 (link) 未能達到降低心血管死亡率及心血管疾病複發率的主要目標** 今年以來，AZN股價下跌6%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IONS":"Ionis Pharmaceuticals, Inc","LU0887340254.USD":"abrdn SICAV I - EUROPEAN SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1003076772.USD":"BGF EUROPEAN EQUITY INCOME \"A5G\" (USDHDG) INC","LU1170363599.USD":"ALLIANZ EUROPE EQUITY GROWTH SELECT \"A\" (USDHDG) INC","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0857590862.USD":"ALLIANZ EUROPE EQUITY GROWTH \"AT\" (USDHDG) H2 ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","LU0047473722.SGD":"HSBC GIF EUROPE VALUE \"PD\" (SGD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2539964713.USD":"SCHRODER ISF EUROPEAN SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","AZN.UK":"阿斯利康制药","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00BKPKM643.USD":"NEUBERGER BERMAN EUROPEAN SUSTAINABLE EQUITY \"A\" (USDHDG) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0345777147.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","03165":"华夏欧优股对冲","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC"},"translate_title":"AstraZeneca becomes the biggest loser on the FTSE 100 as late-stage clinical trial of heart drug fails","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN.UK":0.9,"03165":0.6,"IONS":0.9},"content_text":"BUZZ-<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>因心臟病藥物晚期臨床試驗失敗，成為富時100指數中跌幅最大的個股\n7月9日 - ** 阿斯利康（AZN.L）股價一度暴跌9.6%至12,874便士；有望創下自2017年以來最慘淡的一天** AZN成為富時100指數 .FTSE 中跌幅最大的個股，該指數下跌0.4%** 該公司表示，其與Ionis（IONS.O）合作研發的神經疾病藥物Wainua，在晚期臨床試驗中 (link) 未能達到降低心血管死亡率及心血管疾病複發率的主要目標** 今年以來，AZN股價下跌6%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}